Nimodipina Doc Generici (Nimodipine)

Nimodipine blocks L‑type calcium channels on the smooth muscle of cerebral arteries. This inhibition reduces calcium entry into the cells, causing the vessels to relax and widen. The resulting vasodilation improves cerebral blood flow and counters the narrowing that can occur after a subarachnoid hemorrhage.

The dosage of Nimodipina Doc Generici is determined by the prescribing clinician based on the patient’s condition, age, weight, and renal or hepatic function. Healthcare professionals follow established guidelines and adjust the regimen as needed; patients should not alter the dose without medical advice.

Safety data for nimodipine in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. The potential benefits must be weighed against possible risks, and the medication should only be used if the prescriber deems it essential for the mother’s health.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Nimodipine is a selective L‑type calcium channel antagonist with a high affinity for cerebral vessels, making it especially effective for preventing vasospasm after subarachnoid hemorrhage. Other vasodilators, such as nitroglycerin or hydralazine, act systemically and lack the same degree of cerebral selectivity, which can limit their usefulness in this specific neurovascular indication.

The tablets should be stored at ambient temperature, preferably below 25 °C, in their original container to protect them from moisture and light. Keep the product out of reach of children and avoid storing it in humid environments such as bathrooms.

Nimodipina Doc Generici is taken orally, usually with a glass of water. The tablet should be swallowed whole and not crushed or chewed unless the prescriber provides specific instructions. Administration timing (e.g., with or without food) follows the guidance of the treating physician.

The most critical adverse events include severe hypotension, which can lead to fainting or shock, and rare cardiac complications such as bradycardia or myocardial infarction. Allergic reactions, including rash or angioedema, and significant liver enzyme elevations are also serious concerns that require immediate medical attention.

Patients with known hypersensitivity to nimodipine or any component of the tablet should avoid the product. It is also contraindicated in individuals with severe hypotension, uncontrolled heart failure, or those taking strong CYP3A4 inhibitors without appropriate dose adjustments. Clinicians must assess each patient’s medical history before prescribing.